Introduction
============

Lung cancer is among the most prevalent types of cancer worldwide and represents a serious threat to human health ([@b1-mmr-18-06-4831]). The most common subtype of lung cancer is non-small cell lung cancer (NSCLC), which comprises \~85% of all lung cancer cases ([@b2-mmr-18-06-4831]). Due to a lack of early screening and diagnosis based on specific biological markers, and the unapparent clinical symptoms of early lung cancer, the majority of lung cancer cases are diagnosed at a late stage ([@b3-mmr-18-06-4831]). The 5-year survival rate for lung cancer is \<10% ([@b4-mmr-18-06-4831]). Therefore, it is important to identify novel biomarkers to provide more accurate diagnosis and individualized treatment regimens for patients with lung cancer.

MicroRNAs (miRNA/miRs) are non-coding single-stranded RNAs of \~19--22 nucleotides in length. Numerous studies have demonstrated that miRNAs are involved in the processes of tumorigenesis and tumor development, and serve similar oncogenic roles in cell colonization, apoptosis, migration and other biological processes ([@b5-mmr-18-06-4831]--[@b9-mmr-18-06-4831]). Recent studies have indicated that a number of miRNAs, including miR-126 ([@b10-mmr-18-06-4831],[@b11-mmr-18-06-4831]) and miR-16-1 ([@b12-mmr-18-06-4831]), are involved in the initiation and progression of NSCLC through the regulation of target genes. miR-939 promotes the proliferation of human ovarian cancer cells by repressing adenomatous polyposis coli like-2 expression ([@b13-mmr-18-06-4831]). Decreased expression of miR-939 contributes to the chemoresistance and metastasis of gastric cancer via dysregulation of sodium-dependent phosphate transport protein 2B and the RAF proto-oncogene serine/threonine-protein kinase/dual specificity mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway. mir-939 is also involved in the regulation of breast cancer. Notably, when up taken in exosome-releasing triple negative breast cancer cells, researchers demonstrated that inhibiting miR-939 expression caused downregulation of vascular endothelial cadherin expression ([@b14-mmr-18-06-4831]). Using a number of bioinformatics software packages and platforms, Ma *et al* ([@b15-mmr-18-06-4831]) reported that miR-939 was the most connected miRNA that regulated a large number of genes, and was involved in lung cancer and the nervous system via functional annotation analysis.

The aim of the present study was to observe the function of miR-939 in NSCLC and its mechanism of action, in order to provide data to potentially aid in the early diagnosis and clinical treatment of NSCLC. Additionally, the present study aimed to provide a theoretical basis for the development of novel drugs against genes associated with NSCLC.

Materials and methods
=====================

### Clinical samples

NSCLC samples and the adjacent tissues were obtained from 60 patients (27 males/33 females; age range, 40--70 years) who underwent surgery at the First Affiliated Hospital of Nanjing Medical University (Nanjing, China) from March 2014 to July 2016. Patients who had received radiotherapy and/or chemotherapy were excluded. The specimens were immediately frozen in liquid nitrogen and stored at −80°C until further analysis. Approval to conduct human experiments was obtained from the Ethical Committee at the First Affiliated Hospital of Nanjing Medical University and all patients enrolled in the study signed consent forms. All clinical procedures were conducted in accordance with the guidelines of the Ethical Committee of the First Affiliated Hospital of Nanjing Medical University.

### Cell culture

H1299, SPCA1, A549, H358 and H1650 cells were purchased from the Chinese Academy of Sciences (Shanghai, China). The 16HBE human normal lung cell line was obtained from our laboratory. All cell lines were maintained in Dulbecco\'s modified Eagle\'s medium or RPMI-1640 (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C in a 5% CO~2~ atmosphere.

### RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA of both tissues and cell lines were extracted from the cell lines and clinical samples with a TRIzol kit (Thermo Fisher Scientific, Inc.), used according to the manufacturer\'s protocol. RNA quality was confirmed with a NanoDrop 300 spectrophotometer (Thermo Fisher Scientific, Inc.). RT was performed using a SuperScript II first-strand cDNA synthesis kit (Thermo Fisher Scientific, Inc.). RT was performed at 42°C for 40 min, followed by 70°C for 15 min. The following PCR cycling conditions were used: 95°C for 5 min; followed by 45 cycles of 95°C for 45 sec; 60°C for 60 sec; 72°C for 45 sec. PCR for the detection of miR-939 was performed with an ABI Prism 7900 detection system (Thermo Fisher Scientific, Inc.) using a TaqMan MicroRNA Assay (Thermo Fisher Scientific, Inc.). The primer sequences were as follows: miR-939 forward, TGGGGAGCTGAGGCTCTG and reverse, AGTGCAGGGTCCGAGGTATT; miR-939 RT Primer: GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCACCCC; GAPDH forward, AACTTTGGCATTGTGGAAGG and reverse, CACATTGGGGGTAGGAACAC. miR-939 expression was normalized to the expression level of GAPDH. Relative miR-939 expression was analyzed by the 2^−ΔΔCq^ method ([@b16-mmr-18-06-4831]).

### Transfection

Human miR-939 inhibitor and inhibitor negative control (inhibitor NC) (miR-939 mimics sense, UGGGGAGCUGAGGCUCUGGGGGUG and mimics antisense, CCCCCAGAGCCUCAGCUCCCCAUU; mimics NC sense, UUCUCCGAACGUGUCACGUTT and mimics NC antisense, ACGUGACACGUUCGGAGAATT; inhibitor, CACCCCCAGAGCCUCAGCUCCCCA and inhibitor NC, CAGUACUUUUGUGUAGUACAA) oligonucleotides were synthesized by Guangzhou RiboBio Co., Ltd. (Guangzhou, China). The NSCLC cell lines, H1299 and SPCA1, were transfected with the miR-939 inhibitor and NC using Lipofectamine^®^ 2000 (Thermo Fisher Scientific, Inc.) at a final concentration of 100 nM. Between 2 and 5 days following transfection, NSCLC cells were harvested and RT-qPCR was performed to determine transfection efficiency.

### Proliferation experiment

Cell Counting Kit-8 (CCK-8) experiments were used to detect cell proliferative ability. According to the kit instructions, CCK-8 reagent (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) was added to 4×10^3^ transfected H1299 or SPCA1 cells/well in a 96-well plate, which were incubated at 37°C for 2 h. The optical density of the wells was evaluated at 450 nm with a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). According to the manufacturer\'s protocol, a 5-ethynyl-29-deoxyuridine (EdU) assay (Guangzhou RiboBio Co, Ltd., Guangzhou, China) was additionally performed to detect cell proliferation. In brief, 24 h after transfection, H1299 or SPCA1 cells were incubated with EdU (50 µM) for 2 h at 37°C. Apollo staining (Guangzhou RiboBio Co, Ltd., Guangzhou, China; 400 µl for 30 min at room temperature) and DAPI (Guangzhou RiboBio Co, Ltd.) staining (400 µl for 30 min at room temperature) were performed and the EdU positive cells were evaluated with a fluorescence microscope (×200; Nikon Corporation, Tokyo, Japan). The EdU incorporation rate was calculated as the ratio of EdU-positive cells, to the total number of DAPI-positive cells (blue).

### Transwell assay

Cell invasion was assessed using a 24-well, 8-mm pore size (EMD Millipore, Billerica, MA, USA) and BioCoat Matrigel (BD Biosciences, San Jose, CA, USA). Briefly, transfected H1299 and SPCA1 cells (1×10^5^ cells/well) were plated in the upper chamber in DMEM with 1% FBS. The lower chamber was filled with DMEM with 10% FBS as a chemoattractant. At 24 h following incubation at 37°C in a 5% CO~2~ atmosphere, the upper chamber was removed. Cells that had invaded into the lower chamber were fixed with 70% ethanol at 4°C for 15 min and stained with hematoxylin at room temperature for 15 min. In each well, cell numbers (5×10^4^) in five random rectangular fields were counted under a light microscope (×200), and the average value was used to express the invasive ability of the cells, and then normalized to the cell numbers in control wells. Images were obtained using NIS-Elements Viewer software through a Nikon microscope (Nikon Corporation, Tokyo, Japan).

### Western blot analysis

Total protein of transfected H1299 and SPCA1 were extracted and quantified using a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology, Haimen, China). Cells were lysed in ice-cold radioimmunoprecipitation assay buffer (Beyotime Institute of Biotechnology) with 10 nM phenylmethylsulfonyl fluoride for 30 min at 4°C and collected to extract total protein. The proteins (10 µl) were separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes. The membranes were blocked with 5% fat-free milk at room temperature for 1 h, incubated with mouse monoclonal anti-tissue inhibitor of metalloproteinases 2 (TIMP2; 1:1,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA; cat. no. sc-21735) and anti-GAPDH antibodies (1:1,000; Santa Cruz Biotechnology, Inc.; cat. no. sc-32233). Mouse IgGk binding protein horseradish peroxidase-conjugated secondary antibody (1:1,000; Santa Cruz Biotechnology, Inc.; cat. no. sc-516102) was added for 2 h at room temperature. Bands were visualized with the Pierce ECL Western Blotting substrate (Thermo Fisher Scientific, Inc.) and exposed in a Molecular Imager ChemiDoc XRS system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). According to the manufacturer\'s protocol, the analysis was performed using Image Lab (version 5.2.1; Bio-Rad Laboratories, Inc.) and GAPDH was used as the normalization.

### Luciferase reporter assay

Using the prediction programs miRDB ([mirdb.org](mirdb.org)) and TargetScan Human ([www.targetscan.org](www.targetscan.org)), potential targets of miR-939 were predicted. The binding sites or mutant (mut) sequence of the TIMP2 3′-untranslated region (UTR) was inserted into the *Kpn*I and *Sac*I sites of the pGL3 promoter vector (GenScript, Piscataway, NJ, USA). H1299 cells (5×10^5^ cells/well) were plated onto 6-well plates and were transfected with 100 ng pGL3-TIMP2 or pGL3-TIMP2-mut and miR-939 mimics (50 nM) using Lipofectamine^®^ 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). The 3′-UTR of TIMP2 was determined to contain a binding site for miR-939. After 24 h, the luciferase activity of the constructs was evaluated according to the ratio of firefly fluorescence to *Renilla* fluorescence using a Luciferase Reporter Assay system (Promega Corporation, Madison, WI, USA).

### Statistical analysis

Statistical analysis was performed with Stata software (version 11.0; StataCorp LP, College Station, TX, USA). The data were presented as mean ± standard deviation of three independent experiments. The Student\'s t-test, or two-way analysis of variance followed by Fisher\'s Least Significant Difference test were used to analyze statistical differences. Additionally, the analysis of statistical differences in the clinical factors of patients with NSCLC was conducted using the χ^2^ test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### miR-939 is upregulated in NSCLC tissues

To investigate the underlying function of miR-939 expression in NSCLC progression, clinical specimens were collected from patients with NSCLC, and miR-939 expression was assessed by comparing cancer specimens with adjacent normal lung tissues. RT-qPCR analysis demonstrated that miR-939 was expressed at a higher level in the cancer specimens compared with its expression in the adjacent normal tissues (P\<0.05; [Fig. 1](#f1-mmr-18-06-4831){ref-type="fig"}). In addition, in the analysis of the clinical characteristics of the patients with NSCLC ([Table I](#tI-mmr-18-06-4831){ref-type="table"}), it was observed that increased miR-939 expression was significantly associated with higher tumor stage (stages III--IV; P=0.008), increased tumor size (\>3 cm; P=0.015) and lymphatic metastasis (P=0.001). However, its abnormal expression was not associated with patient age, sex or smoking history. These findings indicated that miR-939 may be involved in the development of NSCLC, and thus subsequent experiments aimed to clarify its potential function.

### miR-939 expression is increased in NSCLC cell lines

The present study focused on investigating the potential function of miR-939 *in vitro*. miR-939 expression was detected in NSCLC cell lines (H1299, SPCA1, A549, H358 and H1650) and a normal lung cell line (16HBE). RT-qPCR analysis demonstrated that miR-939 expression was significantly increased in all NSCLC cell lines compared with that in the 16HBE cell line (P\<0.05; [Fig. 2](#f2-mmr-18-06-4831){ref-type="fig"}).

### miR-939 downregulation inhibits NSCLC cell line proliferation

Subsequently, based on the abnormal expression of miR-939 among the NSCLC cell lines, H1299 and SPCA1 cells that demonstrated the highest miR-939 expression were transfected with an miR-939 inhibitor to detect the regulatory mechanisms affected by miR-939 knockdown in NSCLC development *in vitro*, with inhibitor negative control (NC)-transfected cells as the control. Following transfection of the cells with miR-939 inhibitor or inhibitor NC, it was identified via RT-qPCR that miR-939 was significantly downregulated in the miR-939-silenced cells compared with its expression in the inhibitor NC group (P\<0.01; [Fig. 3A and B](#f3-mmr-18-06-4831){ref-type="fig"}).

Additionally, to investigate the influence of miR-939 on the cell proliferative ability, CCK-8 and EdU assays were performed. In the H1299 and SPCA1 cell lines, the CCK-8 ([Fig. 3C and D](#f3-mmr-18-06-4831){ref-type="fig"}, respectively) and EdU ([Fig. 4A and B](#f4-mmr-18-06-4831){ref-type="fig"}, respectively) assays demonstrated that cell proliferative ability was markedly decreased by the silencing of miR-939 expression.

### miR-939 downregulation inhibits NSCLC invasion

The effect of miR-939 downregulation on the invasion of H1299 and SPCA1 cells was also examined. A Transwell assay demonstrated that compared with the cells transfected with inhibitor NC, a reduced number of cells invaded into the lower chambers in the miR-939 inhibitor group ([Fig. 5A and B](#f5-mmr-18-06-4831){ref-type="fig"}). This data suggested that the knockdown of miR-939 markedly reduced NSCLC invasion.

### miR-939 regulates TIMP2 by binding to its 3′-UTR

In order to define whether TIMP2 had a binding site for miR-939, cells were transfected with miR-939 mimics ([Fig. 6A](#f6-mmr-18-06-4831){ref-type="fig"}) and, using the prediction programs miRDB and TargetScan Human, the underlying target genes of miR-939 were verified. The 3′-UTR of TIMP2 was identified to have a binding site for miR-939 ([Fig. 6B](#f6-mmr-18-06-4831){ref-type="fig"}). To determine whether miR-939 directly targets TIMP2 in NSCLC cells, a luciferase reporter assay was conducted. The results demonstrated a reduction in luciferase activity following co-transfection with miR-939 mimics (P\<0.01), whereas co-transfection with NC had no significant effect on luciferase activity ([Fig. 6C](#f6-mmr-18-06-4831){ref-type="fig"}), which indicated that miR-939 regulated TIMP2 by binding to its 3′-UTR.

Subsequently, the effect of miR-939 downregulation on TIMP2 expression was assessed. Western blot analysis indicated that the silencing of miR-939 increased the protein expression level of TIMP2 in H1299 and SPCA1 cells ([Fig. 6D](#f6-mmr-18-06-4831){ref-type="fig"}). Collectively, these findings demonstrated that miR-939 was able to negatively regulate TIMP2 by binding to its 3′-UTR, although this requires further investigation.

Discussion
==========

Numerous studies have reported that miRNAs function as oncogenes or tumor suppressors in the progression of different types of cancer. Lu *et al* ([@b17-mmr-18-06-4831]) reported that miRNA-221 expression was increased in renal cell carcinoma, and promoted cell proliferation, migration and invasion by regulating TIMP2. In gastric cancer, miR-29a repressed cell migration and invasion by modulating roundabout homolog 1 ([@b18-mmr-18-06-4831]). Low-level expression of miR-329 has been implicated in gastric cancer invasion and growth by targeting T cell lymphoma invasion and metastasis 1 ([@b19-mmr-18-06-4831]). In addition, a number of key miRNAs have been established as biomarkers for early diagnosis and prognosis in a range of malignancy types ([@b5-mmr-18-06-4831]). For instance, the downregulation of miR-197 predicted a poor prognosis for patients with esophageal cancer ([@b20-mmr-18-06-4831]), whereas miR-126 and miR-200c dysregulation has been implicated in the prognosis of patients with NSCLC ([@b21-mmr-18-06-4831]).

In the present study, RT-qPCR analysis demonstrated that the upregulation of miR-939 occurred in NSCLC cell lines and clinical specimens, thus indicating a potential prognostic marker for patients with NSCLC. Furthermore, RT-qPCR analysis identified that differential expression of miR-939 in NSCLC was significantly associated with the patient clinical factors of tumor stage, tumor size and lymphatic metastasis status. In addition, the functional role of miR-939 was investigated *in vitro*. On silencing of miR-939 in the NSCLC cell lines H1299 and SPCA1, inhibition of cell proliferation and invasion was observed. Collectively, these data demonstrated that miR-939 may be involved in the development of NSCLC, although this requires further investigation.

It is established that miRNAs regulate certain target genes by binding to their 3′-UTRs ([@b22-mmr-18-06-4831]--[@b24-mmr-18-06-4831]). miR-124 suppressed gastric cancer development by directly targeting enhancer of zeste homolog 2 ([@b25-mmr-18-06-4831]); whereas, miR-26a, serving as a tumor suppressor, repressed cell proliferation by directly binding the high-mobility group AT-hook 2 3′-UTR in gallbladder cancer ([@b26-mmr-18-06-4831]). Additionally, using the prediction programs miRDB and TargetScan Human, the underlying target genes of miR-939 were verified in the present study. A luciferase reporter assay identified a reduction in luciferase activity following co-transfection with miR-939 mimics, while co-transfection with the negative control did not significantly alter the luciferase activity, indicating that miR-939 regulated TIMP2 by binding to its 3′UTR. Subsequently, the effect of miR-939 downregulation on TIMP2 expression was examined. Western blot analysis indicated that the silencing of miR-939 increased the protein expression level of TIMP2.

Lang *et al* ([@b27-mmr-18-06-4831]) reported miR-429 downregulates TIMP2 expression to promote the proliferation and metastasis of NSCLC cells. Wang *et al* ([@b28-mmr-18-06-4831]) reported that microRNA-15b promotes proliferation and invasion of NSCLC by directly targeting TIMP2. Finally, another study reported that miRNA-221 serves an oncogenic role by directly targeting TIMP2 in NSCLC ([@b29-mmr-18-06-4831]).

The development and progression of lung cancer is not determined by a single or a few factors; rather, it is affected by a number of genes and signaling pathways ([@b30-mmr-18-06-4831],[@b31-mmr-18-06-4831]). The present study was limited due to the sample size and cell line type, and therefore a larger sample size is required. Further experiments are required in order to examine the association between miR-939 and invasion or migration in order to discover any potential regulatory role of miR-939 in the development of lung cancer.

In conclusion, the present study demonstrated that miR-939 was able to regulate NSCLC cell proliferation and invasion. Additionally, miR-939 negatively regulated TIMP2 by binding to its 3′UTR. Therefore, miR-939 may be a potential target in the treatment of NSCLC, although this required further investigation.
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![miR-939 expression is increased in tumor tissues. The relative expression of miR-939 was detected in tumor tissues and adjacent tissues by reverse transcription-quantitative polymerase chain reaction. \*P\<0.05 vs. adjacent tissues. miR, microRNA.](MMR-18-06-4831-g00){#f1-mmr-18-06-4831}

![miR-939 is increased in tumor cell lines. The relative expression of miR-939 was detected in tumor cell lines (H1299, SPCA1, A549, H358 and H1650) and was compared with a normal cell line (16HBE) via reverse transcription-quantitative polymerase chain reaction. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001 vs. 16HBE. miR, microRNA.](MMR-18-06-4831-g01){#f2-mmr-18-06-4831}

![Knockdown of miR-939 inhibits cell proliferation. miR-939 expression was detected in (A) H1299 and (B) SPCA1 cells following transfection with an miR-939 inhibitor by reverse transcription-quantitative polymerase chain reaction, with inhibitor NC-transfected cells as the control group. Cell proliferation was also detected in the (C) H1299 and (D) SPCA1 cells by a Cell Counting Kit-8 assay at 0, 24, 48 and 72 h. \*P\<0.05 and \*\*P\<0.01 vs. respective inhibitor NC group. miR, microRNA; NC, negative control; OD, optical density.](MMR-18-06-4831-g02){#f3-mmr-18-06-4831}

![Downregulation of miR-939 represses cell proliferation. Cell proliferation in (A) H1299 and (B) SPCA1 cells, was detected by EdU assay (magnification, ×200). \*\*P\<0.01 vs. inhibitor NC group. miR, microRNA; NC, negative control.](MMR-18-06-4831-g03){#f4-mmr-18-06-4831}

![Downregulation of miR-939 inhibits cell invasion. Cell invasion in (A) H1299 and (B) SPCA1 cells was investigated by Transwell assay (magnification, ×40). miR, microRNA; NC, negative control.](MMR-18-06-4831-g04){#f5-mmr-18-06-4831}

![TIMP2 is negatively regulated by miR-939. (A) Successful transfection efficiency was determined by reverse transcription-quantitative polymerase chain reaction. \*\*P\<0.01. (B) In the prediction programs miRDB and TargetScan Human, the 3′-UTR of TIMP2 was indicated to have a binding site for miR-939. (C) Relative luciferase activity was evaluated. 1, pGL3-TIMP2; 2, pGL3-TIMP2+miR-939 mimics; 3, pGL3-TIMP2+NC; 4, pGL3-TIMP2 Mutant; 5, pGL3-TIMP2 Mutant+miR-939 mimics; 6, pGL3-TIMP2 Mutant+NC. \*\*P\<0.01 vs. group 1. (D) The relative protein expression of TIMP2 in H1299 (left) and SPCA1 (right) cells was detected by western blot analysis. miR, microRNA; NC, negative control; TIMP2, TIMP metallopeptidase inhibitor 2; UTR, untranslated region; WT, wild-type.](MMR-18-06-4831-g05){#f6-mmr-18-06-4831}

###### 

Association between miR-939 expression and the clinicopathological characteristics of patients with non-small cell lung cancer.

                              Expression of miR-939, n         
  ---------------------- ---- -------------------------- ----- -------------------------------------------------------
  Total                  60   30                         30    
  Age, years                                                   0.793
    ≤50                  25   12                         13    
    \>50                 35   18                         17    
  Sex                                                          0.436
    Male                 27   12                         15    
    Female               33   18                         15    
  Smoke                                                        0.796
    Yes                  31   15                         16    
    No                   29   15                         14    
  TNM stage                                                    0.008^[a](#tfn1-mmr-18-06-4831){ref-type="table-fn"}^
    I--II                36   13                         23    
    III--IV              24   17                           7   
  Tumor size                                                   0.015^[a](#tfn1-mmr-18-06-4831){ref-type="table-fn"}^
    \<3 cm               39   15                         24    
    \>3 cm               21   15                           6   
  Lymphatic metastasis                                         0.001^[a](#tfn1-mmr-18-06-4831){ref-type="table-fn"}^
    No                   38   13                         25    
    Yes                  22   17                           5   

P\<0.05. miR, microRNA; TNM, tumor, node, metastasis.
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